99 results on '"Habot-Wilner Z"'
Search Results
2. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study
- Author
-
Rosenblatt, A., Udaondo, P., Cunha-Vaz, J., Sivaprasad, S., Bandello, F., Lanzetta, P., Kodjikian, L., Goldstein, M., Habot-Wilner, Z., and Loewenstein, A.
- Published
- 2020
3. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study
- Author
-
Rosenblatt A, Udaondo P, Cunha-Vaz J, Sivaprasad S, Bandello F, Lanzetta P, Kodjikian L, Goldstein M, Habot-Wilner Z, Loewenstein A, and ARTES Study Group
- Subjects
REAL-LIFE ,endocrine system diseases ,genetic structures ,PROGRESSION ,LASER ,ASSOCIATION ,GROWTH-FACTOR THERAPY ,PROTOCOL I ,eye diseases - Abstract
To evaluate the efficacy, effect profile, and safety of dexamethasone implant on diabetic macular edema (DME) in a real-life setting, further comparing results by DME duration, previous treatment status, and diabetic control.
- Published
- 2020
4. Increased Incidence Of Susac Syndrome: A Case Series Study
- Author
-
Wilf-Yarkoni, Adi, primary, Elkayam, O., additional, Aizenstein, O., additional, Yahav, O., additional, Furer, V., additional, Zur, D., additional, Goldstein, M., additional, Barequet, D., additional, Hallevi, H., additional, Karni, A., additional, Habot-Wilner, Z, additional, and Regev, K, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Macular findings on optical coherence tomography in cat-scratch disease neuroretinitis
- Author
-
Habot-Wilner, Z, primary, Zur, D, additional, Goldstein, M, additional, Goldenberg, D, additional, Shulman, S, additional, Kesler, A, additional, Giladi, M, additional, and Neudorfer, M, additional
- Published
- 2011
- Full Text
- View/download PDF
6. Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and meta-analysis.
- Author
-
Ostrovsky M, Sela TC, and Habot-Wilner Z
- Abstract
Background: This systematic review and meta-analysis investigated different treatment modalities' effect on the risk of central nervous system lymphoma progression, ocular disease relapse, systemic lymphoma development and overall survival in primary vitreoretinal lymphoma patients., Methods: PubMed, EMBASE, Scopus and the Cochrane Library of clinical trials were searched from inception to April 21, 2024. Cohort, cross-sectional and case series studies were included. Methodological quality was assessed using the NIH quality assessment tools. Heterogeneity between studies was assessed using Chi square test and I
2 statistic. Outcomes were pooled as odds ratios (OR) using fixed-effects models. Risk of publication bias was assessed using a funnel plot., Results: Included were 28 studies with 476 participants. Ocular treatments included intravitreal methotrexate and/or rituximab injections and ocular radiotherapy. Systemic treatments included intravenous and/or intrathecal chemotherapy, whole-brain radiotherapy and autologous stem cell transplantation. Ocular treatment alone, as compared to systemic or combined treatment, resulted in significantly lower risk of central nervous system lymphoma development (OR = 0.54, p = 0.02) and in no significant difference in the risk for progression to systemic disease (OR = 0.38, p = 0.30) or in overall survival. Significantly lower risk of ocular relapse was found in patients receiving ocular or combined therapy as compared to systemic therapy alone (OR = 0.26, p = 0.001). A subgroup analysis, comparing ocular treatment alone and combined treatment, found no significant difference regarding the risk of central nervous system or systemic lymphoma progression, ocular disease relapse and overall survival., Conclusions: No benefit was observed for the addition of systemic therapy to ocular treatment in patients with primary vitreoretinal lymphoma., (© 2024 The Author(s). Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists.)- Published
- 2024
- Full Text
- View/download PDF
7. Ocular Inflammatory Events Following COVID-19 Vaccination in the Paediatric Population: A Multinational Case Series.
- Author
-
Testi I, Brandão-de-Resende C, De-La-Torre A, Concha-Del-Rio LE, Cheja-Kalb R, Mahendradas P, Habot-Wilner Z, Yalçındağ N, Markelj Š, Iriqat S, Portero A, Petrushkin H, Pavesio C, and Solebo AL
- Subjects
- Humans, Male, Female, Child, Adolescent, Child, Preschool, Visual Acuity physiology, Glucocorticoids therapeutic use, Uveitis diagnosis, Uveitis etiology, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Retrospective Studies, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines adverse effects, Vaccination adverse effects, SARS-CoV-2
- Abstract
Background: Ocular inflammatory events following COVID-19 vaccination have been reported in the adult population., Methods: Multinational case series of patients under the age of 18 diagnosed with ocular inflammatory events within 28 days of COVID-19 vaccination., Results: Twenty individuals were included. The most common event was anterior uveitis ( n = 8, 40.0%), followed by intermediate uveitis (7 patients, 35%), panuveitis (4 patients, 20%), and posterior uveitis (1 patient, 5%). The event was noticed in the first week after vaccination in 11 patients (55.0%). Twelve patients (60.0%) had a previous history of intraocular inflammatory event. Patients were managed with topical corticosteroids ( n = 19, 95.0%), oral corticosteroids ( n = 10, 50.0%), or increased dose of immunosuppressive treatment ( n = 6, 30.0%). Thirteen patients (65.0%) had a complete resolution of the ocular event without complications. All patients had a final visual acuity unaffected or less than three lines of loss., Conclusion: Ocular inflammatory events may happen in the paediatric population following COVID-19 vaccination. Most events were successfully treated, and all showed a good visual outcome.
- Published
- 2024
- Full Text
- View/download PDF
8. Reply.
- Author
-
Gomel N, Goldstein M, Fung AT, Iovino C, Tatti F, Peiretti E, Habot-Wilner Z, Loewenstein A, Iglicki M, and Zur D
- Published
- 2024
- Full Text
- View/download PDF
9. POLYPOIDAL LESIONS ASSOCIATED WITH CHOROIDAL NEVI.
- Author
-
Gomel N, Goldstein M, Fung AT, Iovino C, Tatti F, Peiretti E, Habot-Wilner Z, Loewenstein A, Iglicki M, and Zur D
- Subjects
- Humans, Middle Aged, Aged, Retrospective Studies, Endothelial Growth Factors, Choroid pathology, Tomography, Optical Coherence methods, Fluorescein Angiography methods, Intravitreal Injections, Choroid Diseases drug therapy, Choroid Neoplasms pathology, Nevus, Polyps drug therapy
- Abstract
Purpose: To investigate eyes with polypoidal lesions associated with choroidal nevi, their multimodal imaging characteristics, and long clinical follow-up., Methods: Multicenter, retrospective case series study of patients with polypoidal lesions overlying choroidal nevi. Demographic and clinical information were recorded. Multimodal imaging including color fundus photography, optical coherence tomography, optical coherence tomography angiography, fundus fluorescein angiography, indocyanine angiography, and A- and B-scan ultrasonography were analyzed for nevus and polypoidal lesion characteristics., Results: Fourteen eyes (14 patients; mean age: 70.3 ± 6.7 years) with polypoidal lesions overlying choroidal nevi were included. The mean follow-up duration was 50.0 ± 27.9 months (range 12-108). All nevi were pigmented on color fundus photography, flat on ultrasonography with a mean basal diameter of 3.8 ± 0.4 mm. In all but one eye, optical coherence tomography showed a shallow irregular pigment epithelium detachment overlying the nevus. A total of 11/14 eyes (78.6%) had exudative activity, 9 eyes received intravitreal anti-vascular endothelial growth factor injections, and one eye required intravitreal anti-vascular endothelial growth factor combined with photodynamic therapy. Mean visual acuity was 20/32 at baseline and 20/50 at final visit., Conclusion: We present the largest known cohort of eyes with polypoidal lesions associated with choroidal nevi with up to 9 years follow-up. The exudative degree of the polypoidal lesion in this condition is variable and treatment decisions should be taken on an individual basis. We hypothesize that choroidal ischemia because of altered choroidal vasculature rather than Haller layer hyperpermeability plays a role in the formation of polypoidal lesions overlying nevi.
- Published
- 2024
- Full Text
- View/download PDF
10. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.
- Author
-
Pleyer U, Al-Mutairi S, Murphy CC, Hamam R, Hammad S, Nagy O, Szepessy Z, Guex-Crosier Y, Julian K, Habot-Wilner Z, and Androudi S
- Subjects
- Adult, Humans, Adalimumab therapeutic use, Quality of Life, Prospective Studies, Treatment Outcome, Panuveitis drug therapy, Uveitis
- Abstract
Background/aim: This study evaluated real-life adalimumab impact in patients with active non-infectious intermediate, posterior, or panuveitis (NIIPPU)., Methods: Adults with active NIIPPU received adalimumab in this prospective, observational study (06/2017-04/2020). Patients were evaluated at baseline (V0) and four follow-up visits over 12 months (V1-V4)., Primary Endpoint: proportion of patients achieving quiescence (anterior chamber (AC) cells grade and vitreous haze (VH) grade≤0.5+ in both eyes, no new active chorioretinal lesions) at any follow-up visit. Secondary endpoints: proportion of patients achieving quiescence at each visit; proportion of patients maintaining response; and proportion of patients with flares. Workability, visual function, healthcare resource utilisation, and safety were evaluated., Results: Full analysis set included 149 patients. Quiescence at any follow-up visit was achieved by 129/141 (91%) patients. Quiescence at individual visits was achieved by 99/145 (68%), 110/142 (77%), 102/131 (78%), and 99/128 (77%) patients at V1-V4, respectively. Number of patients in corticosteroid-free quiescence increased from 51/147 (35%; V1) to 67/128 (52%; V4; p<0.05). Proportion of patients with maintained response increased from 89/141 (63%; V2) to 92/121 (76%; V4; p<0.05) and proportion of patients with flare decreased from 25/145 (17%; V1) to 13/128 (10%; V4; p=0.092). Workability and visual function improved throughout the study. Proportion of patients with medical visits for uveitis decreased from 132/149 (89%; V0) to 27/127 (21%; V4). No new safety signals were observed., Conclusion: These results demonstrated adalimumab effectiveness in improving quality of life while reducing economic burden of active NIIPPU., Competing Interests: Competing interests: UP has served as a principal investigator or consultant for AbbVie, Alcon, Allergan, Dompé, Novartis, Santen, Shire, and Thea. CM received research grant funding, speaker fees and honoraria, and conference sponsorship from AbbVie. RH received research grant funding from AbbVie, speaker fees from AbbVie and Amgen, and served as a consultant for Novartis. KJ has served as a principal investigator and consultant for AbbVie. YG-C has served as a principal investigator for AbbVie. SH is an employee of AbbVie and may hold AbbVie stock or options. ON was an employee of AbbVie at the time of the study and is a current contractor of AbbVie and may hold AbbVie stock or options. ZH-W served as a consultant and received speaker fees from AbbVie. SA received research support from AbbVie, Alcon, Allergan, Bayer, Novartis, Roche, Servier, and Xoma., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
11. Gender related trends among Israeli ophthalmologists professional career and personal life performance.
- Author
-
Barequet IS, Rosenblatt A, Schaap Fogler M, Pedut-Kloizman T, Gaton D, Loewenstein A, and Habot-Wilner Z
- Subjects
- Child, Humans, Male, Female, Adult, Middle Aged, Israel, Surveys and Questionnaires, Ophthalmologists, Ophthalmology, Internship and Residency
- Abstract
Background: Gender-diversity trends in ophthalmology in Israel have not been studied despite a high proportion of female ophthalmologists. Our purpose was to evaluate gender-related trends in ophthalmology professional career and personal life performance in early and advanced careers in Israel., Methods: A survey based on a nationwide voluntary anonymous web questionnaire was distributed to the members of the Israeli Ophthalmological Society. The questionnaire included questions referring to professional career and personal life performance. Gender differences were analyzed., Results: Out of 252 respondents, 116 (46%) were women, with a mean age of 47.97 + -11.3 and 53.18 + -12.4 (P = 0.01) years, respectively. Marital status, post-residency fellowship performance or duration, an additional academic degree, academic appointments, and managerial positions were similar between genders. Fellowship predominance of males was found in cornea/cataract/refractive and of females in strabismus, pediatric ophthalmology, and neuro-ophthalmology (P < 0.01, P = 0.032, respectively). Men had significantly more publications and appointments in peer review journals and work hours (P = 0.04 and P = 0.02, P = 0.027, respectively). Both genders responded similarly regarding work satisfaction, combination between family life and work. More women felt inequity during and post-residency in clinical (P = 0.011, P = 0.001, respectively) and surgical work (P = 0.001, P = 0.035, respectively). More women experienced inappropriate remarks from patients and sexual harassment (P = 0.001, P < 0.001, respectively), and supported the need for affirmative action (P < 0.0001)., Conclusions: Several gender disparities were found among ophthalmologists in Israel, including subspecialties distributions, publications, appointments in peer review journals, working hours, work inequity sense, harassment events, and support the need for affirmative action., (© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
- Published
- 2023
- Full Text
- View/download PDF
12. Online support group for patients with inflammatory eye disease: Characterisation of members and assessment of benefits.
- Author
-
Ostrovsky M, Rosenblatt A, Hollander N, and Habot-Wilner Z
- Abstract
Background: Support groups in ophthalmology may be of utmost importance for patients and caregivers. We aimed to characterise members of an online support group for patients and parents of children with inflammatory eye disease and assess the members' expectations and perceived benefits., Methods: A survey based on a voluntary, anonymous web questionnaire was distributed to the members of the 'Lirot' association online support group. The questionnaire included demographic, ocular and systemic information, functional and psychosocial data, support group use patterns, expectations and perceived benefits. Analysis was done for patients and parents., Results: Out of 67 respondents, 43 (64%) were patients, and 24 (36%) were parents. Fifty-eight (88%) were women. The mean age of respondents was 42.9 ± 1.34 years. Anterior uveitis was the most common, and most patients had good visual acuity (<0.3 logMAR). Parents reported higher anxiety levels (p = 0.044) and a more significant effect of their child's disease on their general function (p = 0.005). Most members sought several experts' opinions, psychological treatments and alternative medicine. All members used the WhatsApp group, while only approximately half used Facebook (p < 0.001). Members' expectations were fulfilled for social support, a sense of shared experience and being able to help others, but not for receiving information (p < 0.001). All members reported being willing to recommend the group to others., Conclusions: Support group participation benefited group members. We suggest that ophthalmologists encourage their inflammatory eye disease patients to use online support groups, which may significantly improve their well-being., (© 2023 The Authors. Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists.)
- Published
- 2023
- Full Text
- View/download PDF
13. Retinal vascular occlusions in ocular Behçet disease - a comparative analysis.
- Author
-
Ostrovsky M, Ramon D, Iriqat S, Shteiwi A, Sharon Y, Kramer M, Vishnevskia-Dai V, Sar S, Boulos Y, Tomkins-Netzer O, Lavee N, Ben-Arie-Weintrob Y, Pizem H, Hareuveni-Blum T, Schneck M, Gepstein R, Masarwa D, Nakhoul N, Bakshi E, Shulman S, Goldstein M, Anouk M, Rosenblatt A, and Habot-Wilner Z
- Subjects
- Humans, Male, Adult, Female, Retrospective Studies, Case-Control Studies, Behcet Syndrome complications, Behcet Syndrome diagnosis, Behcet Syndrome epidemiology, Retinal Artery Occlusion diagnosis, Retinal Artery Occlusion epidemiology, Retinal Artery Occlusion etiology, Retinal Vein Occlusion diagnosis, Retinal Vein Occlusion epidemiology, Retinal Vein Occlusion etiology
- Abstract
Purpose: The literature on retinal vascular occlusions in Behçet disease (BD) patients is limited. The aim of this study is to thoroughly investigate retinal vascular occlusions among ocular BD patients., Methods: Retrospective, multicentre case-control study. Three-hundred and three eyes of 175 patients with ocular BD, from 13 hospitals in Israel and Palestine, were included. Patients were assigned into two groups according to the presence of retinal vascular occlusion. Epidemiology, systemic and ocular manifestations, treatments and outcomes were compared between the groups and risk factors for retinal vascular occlusions were identified., Results: One hundred twenty-five patients (71.4%) were male. The mean age at presentation was 28.2 ± 0.86 years. Retinal vascular occlusions were found in 80 eyes of 54 (30.9%) patients, including branch retinal vein occlusion (51.3%), peripheral vessels occlusions (32.5%), central retinal vein occlusion (13.8%) and arterial occlusions (7.5%). Systemic manifestations were similar among both groups. Anterior uveitis was more common in non-occlusive eyes (p < 0.01). Non-occlusive retinal vasculitis (p = 0.03) and ocular complications were more common in occlusive eyes (p < 0.01). Treatments including mycophenolate mofetil, Infliximab or a combination therapy of anti-metabolite and calcineurin inhibitor were more commonly used by occlusive patients (p < 0.05). Occlusive patients underwent more cataract surgeries (p = 0.03). The occlusive group had worse mean best-corrected visual acuity (BCVA) throughout follow-up (p < 0.01). Risk factors for retinal vascular occlusions included male sex and Jewish ethnicity (p < 0.05)., Conclusion: Retinal vascular occlusions were found in a third of ocular BD patients. Occlusive eyes had a worse prognosis. Risk factors for vascular occlusions were identified., (© 2023 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
14. COVID Vaccine-Associated Uveitis.
- Author
-
Habot-Wilner Z, Neri P, Okada AA, Agrawal R, Xin Le N, Cohen S, Fischer N, Kilmartin F, Coman A, and Kilmartin D
- Subjects
- Humans, SARS-CoV-2, Vaccination adverse effects, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Uveitis diagnosis, Uveitis epidemiology, Uveitis etiology, Vaccines
- Abstract
Purpose: Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed., Methods: A literature review of uveitis post various SARS-CoV-2 vaccinations., Results: Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt-Koyanagi-Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases., Conclusion: Uveitis following Covid vaccinations is uncommon and has a good prognosis.
- Published
- 2023
- Full Text
- View/download PDF
15. Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations.
- Author
-
Cohen S, Olshaker H, Fischer N, Vishnevskia-Dai V, Hagin D, Rosenblatt A, Zur D, and Habot-Wilner Z
- Subjects
- Humans, ChAdOx1 nCoV-19, Herpesvirus 3, Human genetics, Retrospective Studies, SARS-CoV-2, Simplexvirus, Vaccination adverse effects, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Herpes Zoster Ophthalmicus diagnosis, Herpes Zoster Ophthalmicus drug therapy, Herpes Zoster Ophthalmicus etiology, Keratitis, Herpetic diagnosis, Keratitis, Herpetic etiology
- Abstract
Purpose: To describe herpetic ocular infections following SARS-CoV-2 vaccinations., Methods: A retrospective study of herpetic ocular infections after BNT162b2mRNA vaccination and a literature review., Results: A cohort of five patients: three varicella zoster virus (VZV) and two herpes simplex virus (HSV) cases, as well as 19 literature cases: 9 cases of VZV and 10 cases of HSV post BNT162b2mRNA, AZD1222, mRNA-1273, and CoronaVac vaccinations. All cases presented within 28 days post vaccination. Most VZV and HSV cases (15/19) reported in the literature presented post first vaccine dose, while in our cohort 2 VZV cases presented post second dose and both HSV cases and one VZV case post third dose. The most common presentations were HZO with ocular involvement and HSV keratitis. All eyes had complete resolution; however, one had retinal detachment and three corneal scars., Conclusion: Herpetic ocular infections may develop shortly after SARS-CoV-2 vaccinations. Overall, the outcome is good.
- Published
- 2023
- Full Text
- View/download PDF
16. Risk factors and clinical significance of prechoroidal cleft in eyes with neovascular age-related macular degeneration in Caucasian patients.
- Author
-
Kredi G, Iglicki M, Gomel N, Hilely A, Loewenstein A, Habot-Wilner Z, and Zur D
- Subjects
- Humans, Angiogenesis Inhibitors therapeutic use, Vascular Endothelial Growth Factor A, Retrospective Studies, Clinical Relevance, Intravitreal Injections, Retinal Pigment Epithelium, Risk Factors, Retinal Detachment drug therapy, Macular Degeneration drug therapy
- Abstract
Objective: The objective of the study was to investigate the prevalence, risk factors and clinical significance of prechoroidal cleft (PC) among neovascular age-related macular degeneration (nAMD) patients in a Caucasian population., Design: A retrospective observational cohort study., Methods: A total of 140 patients with naive nAMD were treated with anti-vascular endothelial growth factor (VEGF) injections and a follow-up of ≥24 months. Optical coherence tomography (OCT) scans were graded for the presence of PC, central subfield foveal thickness (CSFT), maximal retinal thickness (MRT), pigment epithelial detachment (PED), presence of intraretinal fluid (IRF), subretinal fluid (SRF) and subretinal hyper-reflective material (SHRM) at baseline, 3, 6, 12 and 24 months. Best corrected visual acuity (BCVA) and anti-VEGF treatments were recorded., Results: Out of 140, 21 eyes (15%) developed PC. BCVA improved significantly from 0.68 ± 0.56 to 0.62 ± 0.59 logMAR after 24 months (p = 0.008). The change in BCVA was not related to the presence of cleft (p = 0.208). Multivariate analysis confirmed that higher baseline CSFT (p = 0.011, OR = 1.004, 95%, CI 1.001-1.007) and the presence of multi-layered PED (p < 0.001, OR = 21.153, 95%, CI 5.591-80.026) were both predictive for development of PC. Eyes with PC received more injections than eyes without PC., Conclusion: Prechoroidal cleft was found in 15% of Caucasian nAMD patients treated with anti-VEGF injections and was related to greater retinal and PED height, as well as presence of multi-layered PED. Eyes with PC required more anti-VEGF injections. The presence of PC correlates with disease activity, and intensive anti-VEGF suppression can preserve vision., (© 2022 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
17. The challenge in the diagnosis and management of vitreoretinal lymphoma.
- Author
-
Habot-Wilner Z, Pe'er J, and Frenkel S
- Subjects
- Humans, Vitreous Body pathology, Retinal Neoplasms diagnosis, Retinal Neoplasms therapy, Retinal Neoplasms pathology, Eye Neoplasms pathology, Intraocular Lymphoma diagnosis, Intraocular Lymphoma drug therapy, Intraocular Lymphoma pathology
- Published
- 2023
- Full Text
- View/download PDF
18. Ocular Behçet Disease-Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset.
- Author
-
Ostrovsky M, Rosenblatt A, Iriqat S, Shteiwi A, Sharon Y, Kramer M, Vishnevskia-Dai V, Sar S, Boulos Y, Tomkins-Netzer O, Lavee N, Ben-Arie-Weintrob Y, Pizem H, Hareuveni-Blum T, Schneck M, Gepstein R, Masarwa D, Nakhoul N, Bakshi E, Shulman S, Goldstein M, Ramon D, Anouk M, and Habot-Wilner Z
- Abstract
Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and outcomes between three age groups: juvenile (<18 years), adult (18-39 years) and late (≥40 years) disease onset. The study included 175 ocular BD patients (303 eyes) from Israel and Palestine: juvenile-onset ( n = 25, 14.3%), adult-onset ( n = 120, 68.6%) and late-onset ( n = 30, 17.1%). Most patients in all groups were male. Systemic manifestations were similar in all groups. Systemic co-morbidities were more common in late-onset patients. Bilateral panuveitis was the most common ocular manifestation in all patients. Non-occlusive retinal vasculitis, peripheral vessel occlusions, cataract and elevated intraocular pressure were found more commonly among juvenile-onset eyes. Anterior uveitis and macular ischemia were most common among late-onset eyes, while branch retinal vein occlusion was most common in adult and late-onset eyes. All patients were treated with corticosteroids. Methotrexate, immunomodulatory combinations and biologic treatments were more commonly used for juvenile-onset patients. All groups had a similar visual outcome. Our study showed that patients with ocular BD have varied ocular manifestations and require different treatments according to age of disease onset, but visual outcome is similar.
- Published
- 2023
- Full Text
- View/download PDF
19. [SOLVING A MEDICAL MYSTERY THROUGH THE EYES OF A YOUNG PATIENT WITH BUDD-CHIARI SYNDROME AND A NEW VISION LOSS].
- Author
-
Rabinovitch T and Habot-Wilner Z
- Subjects
- Male, Humans, Tumor Necrosis Factor Inhibitors, Vision Disorders, Budd-Chiari Syndrome diagnosis, Budd-Chiari Syndrome etiology, Budd-Chiari Syndrome surgery, Behcet Syndrome complications, Behcet Syndrome diagnosis, Uveitis
- Abstract
Introduction: Budd-Chiari syndrome is a heterogeneous group of disorders characterized by venous drainage obstruction of the liver and is extremely rare. The clinical manifestations are usually ascites, varicose veins and in severe cases - hepatic insufficiency. Behcet's disease is a chronic, idiopathic, inflammatory disease that manifests as obstructive vasculitis and affects a variety of organ systems. Ocular involvement occurs in approximately 70% of the patients, and is a major clinical criterion in the diagnosis. Rarely, Behcet's disease can be a cause of Budd-Chiari syndrome. In these cases, the diagnosis has a crucial impact on the treatment and prognosis of the patients since patients with Budd-Chiari syndrome secondary to Behcet's disease, will usually improve under systemic medications with no need for surgery. In addition, in these patients there is a higher chance for developing hepatocellular carcinoma so they need to have a tight and a long follow-up., Discussion: In this article we discuss a case of a young patient with Budd-Chiari syndrome, who was examined due to acute vision loss in his left eye. Left eye examination revealed panuveitis presenting with anterior uveitis, intermediate uveitis and an occlusive retinal vasculitis. The ocular examination raised suspicion that the diagnosis was Behcet's disease. Actually, Budd-Chiari syndrome was part of the presentation of Behcet's disease, which was not diagnosed until he was examined by us. The patient was treated with corticosteroid therapy and biological treatment with adalimumab, an anti-TNF drug. During follow-up, a complete resolution of the intraocular inflammation was achieved, as well as stabilization of its general condition, with the disappearance of the clinical signs indicative of liver failure.
- Published
- 2022
20. Susac's syndrome - A new ocular finding and disease outcome.
- Author
-
Dinah Zur, Michaella Goldstein, Barequet D, Oron Y, Elkayam O, Karni A, Wilf-Yarkoni A, Regev K, and Habot-Wilner Z
- Subjects
- Adult, Humans, Magnetic Resonance Imaging methods, Retrospective Studies, Microaneurysm, Susac Syndrome diagnosis, Susac Syndrome therapy
- Abstract
Background: Susac's syndrome, a rare autoimmune vasculo-occlusive disease, may pose a diagnostic challenge and result in a devastating ocular and systemic outcome. Our study identifies a new retinal finding and evaluates disease outcome. We aimed to assess clinical and imaging findings, systemic manifestations and disease outcome in patients with ocular Susac's syndrome under immunosuppressive/immunomodulation therapies., Methods: Retrospective tertiary center study including patients with a diagnosis of Susac's syndrome with >12 months follow up. Medical record review including ocular, neurological and auditory clinical and imaging findings, and treatment modalities. Main outcome measures were clinical manifestations and disease outcome., Results: Seven patients (14 eyes) with a mean age of 34.1 years were included. Mean follow-up was 31.9 months (12.4-72.4). All had bilateral ocular disease. Retinal microaneurysms, a new ocular finding, were demonstrated in 5 patients and persisted at the final visit. In 5 eyes, they further extended during follow-up. All were treated with immunosuppressive drugs and 5/7 additional immunomodulation therapy. At last examination, best corrected visual acuity was >20/40 in all eyes, 1/10 eyes had visual field deterioration, no eye had active ocular disease, all patients achieved neurological stability, and 1 patient had auditory deterioration., Conclusion: Retinal microaneurysms, a new ocular finding in Susac's syndrome, were present in most of our patients, indicating ischemic retinal damage. Immunosuppressive and immunomodulation therapies seem to be highly effective in the control of disease activity., (© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
- Published
- 2022
- Full Text
- View/download PDF
21. The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis.
- Author
-
Rubin S, Ohana O, Goldberg O, Peled O, Gendler Y, Habot-Wilner Z, Levinsky Y, Tal R, Harel L, and Amarilyo G
- Subjects
- Anti-Inflammatory Agents therapeutic use, Child, Child, Preschool, Female, Glucocorticoids therapeutic use, Humans, Infant, Male, Recurrence, Arthritis, Juvenile drug therapy, Injections, Intra-Articular, Triamcinolone Acetonide analogs & derivatives, Triamcinolone Acetonide therapeutic use
- Abstract
Objectives: Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatic disease. Intra-articular corticosteroids joint injection (IAJI), with triamcinolone hexacetonide (TH) or triamcinolone acetonide (TA), is an effective additional treatment for oligo and polyarticular JIA. Previous studies have shown the benefits of TH over TA; however, TA is still used in many pediatric rheumatology centers. Our unit has experience with both regimens, and therefore we aimed to compare the efficacy and safety of TA versus TH for JIA patients., Methods: Chart review of JIA patients who were randomly (based on drug availability) treated with TA or TH IAJI during 2010-2019. Primary outcomes for efficacy were defined as full recovery from arthritis one month after IAJI and a relapse rate of arthritis 3 months after IAJI. Primary outcome for safety was defined as the occurrence of adverse events (AEs) during the follow up period after IAJI., Results: Overall, 292 joints of 102 JIA patients were treated (138 TA/154 TH joints). Complete recovery after one month was documented in 107 (69.6%) of TA treated joints and 96 (69.5%) of TH treated joints (P = 0.232). However, rate of relapse after 3 months was significantly higher for TA treated joints (27 (20.1%) vs. 13 (8.8%), respectively, P < 0.01). No AEs were documented except minor scars at four joint injection sites., Conclusion: The recovery from arthritis was similar (~ 70%) with both regimens, however relapse rate was more than double in TA as compared to TH injected joints. These findings are important due to a contemporary shortage of TH in the US market., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
22. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis.
- Author
-
Bomze D, Meirson T, Hasan Ali O, Goldman A, Flatz L, and Habot-Wilner Z
- Subjects
- Databases, Factual, Humans, Immunotherapy adverse effects, Pharmacovigilance, Retrospective Studies, Immune Checkpoint Inhibitors adverse effects, Neoplasms drug therapy
- Abstract
Purpose: Characterize ocular adverse events (oAEs) caused by immune checkpoint inhibitors (ICIs)., Methods: Retrospective analysis of 41,674 cancer patients in the FDA Adverse Event Reporting System (FAERS) pharmacovigilance database receiving anti-PD-1/PD-L1, anti-CTLA-4, or anti-PD-1+ anti-CTLA-4 combination. Reporting odds ratio (ROR) was used to approximate oAE rate across regimens and indications., Results: The most common indications were lung cancer (27.3%) and melanoma (22.7%); 76.3% received anti-PD-1/PD-L1 monotherapy. 1,268 patients (3.0%) reported oAEs, namely vision disorders (30.8%), uveitis (15.1%), and retinal, lacrimal, and optic nerve disorders (10.7%, 9.0%, 8.4%). Melanoma showed the highest proportion of uveitis (117/9,471 cases; 1.2%). Addition of anti-CTLA-4 to anti-PD-1 increased the ROR of uveitis from 4.77 (95% CI 3.83-5.94) to 17.1 (95% CI 12.9-22.7). Among anti-PD-1/PD-L1 cases, uveitis was differentially reported in melanoma (ROR 14.7, 95% CI 10.7-20.2) compared with lung cancer (ROR 2.67, 95% CI 1.68-4.23)., Conclusion: ICI-induced oAEs are rare, and uveitis is significantly associated with melanoma and anti-PD-1+ anti-CTLA-4 combination.
- Published
- 2022
- Full Text
- View/download PDF
23. Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy.
- Author
-
Gomel N, Levinger E, Ram R, Limon D, and Habot-Wilner Z
- Abstract
Acute lymphoblastic leukemia (ALL) is a malignant neoplasm of the blood stem cells, characterized by increased formation of immature lymphocytes. Ocular manifestations may vary with ocular, adnexal, and orbital involvement. In this case report, we describe the first case of extramedullary relapse of ALL limited to the anterior chamber of the eye treated with the novel chimeric antigen receptor T (CAR T)-cell therapy and provide a literature review of cases of ALL relapse in the anterior chamber. A 21-year-old male with a history of B-cell ALL presented with a unilateral blurry vision in his left eye. Ocular examination revealed the presence of cells +3 in the anterior chamber and a 1.5-mm hypopyon. Anterior chamber aspiration confirmed a B-ALL relapse. The patient was successfully treated with radiotherapy of his left eye and received CTL-019 transduced T cells (tisagenlecleucel; Novartis) with cytarabine as a bridging chemotherapy treatment. On the last examination, 18 months after the first presentation, the patient presented a complete ocular remission with no systemic or CNS involvement. ALL relapse may involve the anterior chamber of the eye, and an accurate diagnosis is crucial to enable a fast and appropriate treatment. Novel CAR T-cell immunotherapy, combined with ocular irradiation, may be considered in such cases., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2021 by The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
24. Bilateral Diffuse Uveal Melanocytic Proliferation in a Woman with Metastatic Scalp Squamous Cell Carcinoma Treated with Cemiplimab.
- Author
-
Katzburg E, Zur D, Gutfeld O, Kirgner I, and Habot-Wilner Z
- Abstract
Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a rare paraneoplastic intraocular syndrome that causes progressive visual loss in patients driven by an IgG factor associated with an underlying malignancy. The IgG factor - cultured melanocyte elongation and proliferation - was found in the IgG fraction of the serum of BDUMP patients. It has been shown to be involved in melanocytic proliferation. In this case report, we describe the first case of BDUMP related to metastatic cutaneous squamous cell carcinoma (cSCC) of the scalp. A 61-year-old woman complained of decreased vision in both of her eyes, while being treated with cemiplimab (an anti-PD-1 therapy) for metastatic cSCC. Fundus examination showed hypopigmented lesions in a leopard pattern and pigmentary clumps in both eyes. Further imaging confirmed the diagnosis of BDUMP. The patient was successfully treated with plasmapheresis. During follow-up, cataract progressed in both eyes, and she underwent cataract surgery with visual acuity improvement to 20/20. BDUMP is a challenging diagnosis especially in patients treated with anti-PD-1 immunotherapy as it can be confused with drug-related effects. It is crucial to distinguish between the cases in order to allow the appropriate treatment which includes continuation of systemic anti-PD-1 for the underlying malignancy and plasmapheresis therapy for BDUMP., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2021 by The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
25. UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION: A Possible Association.
- Author
-
Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, Shaer B, Vishnevskia-Dai V, Shulman S, Newman H, Biadsy M, Masarwa D, Fischer N, Yovel O, Goldfeather-Ben Zaken S, and Habot-Wilner Z
- Subjects
- Adult, Aged, Drug-Related Side Effects and Adverse Reactions diagnosis, Female, Humans, Male, Middle Aged, Retrospective Studies, Uveitis, Anterior diagnosis, Young Adult, BNT162 Vaccine adverse effects, COVID-19 prevention & control, Drug-Related Side Effects and Adverse Reactions etiology, SARS-CoV-2, Uveitis, Anterior chemically induced, Vaccination adverse effects
- Abstract
Purpose: To describe uveitis cases after the BNT162b2 mRNA SARS-CoV-2 vaccination., Methods: This is a multicenter, retrospective study. Vaccine-related uveitis diagnosis was supported by the classification of the World Health Organization Adverse Drug Terminology and the Naranjo criteria., Results: Twenty-one patients (23 eyes) with a mean age of 51.3 years (23-78 years) were included. Eight of the 21 patients had a known history of uveitis. The median time from previous to current attack was 1 year (0.5-15 years). There were 21 anterior uveitis cases, two with bilateral inflammation. Eight cases occurred after the first vaccination and 13 after the second vaccination. All but three presented as mild to moderate disease. Two patients developed multiple evanescent white dot syndrome after the second vaccination. The mean time from vaccination to uveitis onset was 7.5 ± 7.3 days (1-30 days). At final follow-up, complete resolution was achieved in all but two eyes, which showed significant improvement. One case of severe anterior uveitis developed vitritis and macular edema after the second vaccination, which completely resolved after an intravitreal dexamethasone injection., Conclusion: Uveitis may develop after the administration of the BNT162b2 mRNA vaccine. The most common complication was mild to moderate anterior uveitis, while multiple evanescent white dot syndrome can also occur less frequently.
- Published
- 2021
- Full Text
- View/download PDF
26. Uveitis Induced by Biological Agents Used in Cancer Therapy.
- Author
-
Deitch-Harel I MD, Raskin E MD, Habot-Wilner Z MD, Friling R MD, Amer R MD, and Kramer M MD
- Subjects
- Acrylamides adverse effects, Adolescent, Adult, Aged, 80 and over, Aniline Compounds adverse effects, Female, Glucocorticoids therapeutic use, Humans, Ipilimumab adverse effects, Male, Middle Aged, Nivolumab adverse effects, Retrospective Studies, Uveitis, Anterior diagnosis, Uveitis, Anterior drug therapy, Vemurafenib adverse effects, Antineoplastic Agents adverse effects, Drug-Related Side Effects and Adverse Reactions etiology, Immune Checkpoint Inhibitors adverse effects, Neoplasms drug therapy, Uveitis, Anterior chemically induced
- Abstract
Purpose : To report cases of uveitis induced by biological therapy given for cancer. Methods : Retrospective review of medical charts of patients. Results : Included were six patients aged 14-81 years. Three were treated with vemurafenib and one each with nivolumab, ipilimumab, and osimertinib. The oncological diagnoses were metastatic thyroid carcinoma, pleomorphic xanthoastrocytoma, metastatic melanoma, adenocarcinoma of the lung, and metastatic breast cancer. Ocular manifestations appeared 4-82 weeks after the biological treatment was initiated. The most common ocular presentation was anterior uveitis. Onset was sudden in all cases. The median duration of uveitis was 70 weeks. Treatment included topical or systemic corticosteroids; one patient received a single intravitreal steroid injection in one eye. Conclusions : Uveitis may rarely be induced by treatment with biological agents for cancer. Both oncologists and ophthalmologists should be aware of this potential side effect. Early detection and management can prevent permanent complications and save the patient's vision.
- Published
- 2021
- Full Text
- View/download PDF
27. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
- Author
-
Habot-Wilner Z, Frenkel S, and Pe'er J
- Subjects
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors therapeutic use, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic adverse effects, Bevacizumab therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Corneal Diseases chemically induced, Delayed Diagnosis, Endophthalmitis chemically induced, Female, Humans, Intraocular Lymphoma diagnosis, Intraocular Lymphoma pathology, Intravitreal Injections, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Neovascularization, Pathologic drug therapy, Neovascularization, Pathologic etiology, Ocular Hypertension chemically induced, Remission Induction, Retinal Neoplasms diagnosis, Retinal Neoplasms pathology, Retrospective Studies, Treatment Outcome, Vitreous Body pathology, Young Adult, Antimetabolites, Antineoplastic therapeutic use, Intraocular Lymphoma drug therapy, Methotrexate therapeutic use, Retinal Neoplasms drug therapy
- Abstract
Vitreo-retinal lymphoma (VRL) is the most common intraocular lymphoma and is highly associated with central nervous system (CNS) lymphoma (CNSL), both posing a therapeutic challenge. We investigated patients' characteristics, efficacy and safety of intravitreal methotrexate (MTX) injections and their outcomes over 20 years. The records of 129 patients diagnosed between 1997 and 2018 were retrospectively reviewed. Lymphoma involved both the CNS and vitreo-retina (49%), solely the CNS (37%) or solely the vitreo-retina (14%). In all, 45·5% of the patients with CNSL either presented with VRL or developed it after a mean (±SE) of 85·7 (7·3) months. In all, 66·0% of the patients diagnosed with VRL either presented with CNSL or developed it after a mean (±SE) 42·6 (7·6) months. The 81 patients with VRL (134 eyes) received a mean (±SD) of 19 (7) injections; however, only 5 (4) injections were needed to reach complete remission. Local recurrence occurred in two of the 81 patients. Overall, 80·2% of eyes had an initial moderate-severe visual loss, and >50% of them improved. Reversible keratopathy was the most prevalent side-effect. A total of 18·5% developed intraocular pressure (IOP) elevation due to angle neovascularisation after 16 injections, which could be reversed with prompt intravitreal injection of bevacizumab. Intravitreal MTX injections are a safe and effective treatment for VRL. Fewer injections (15) may offer similar results with fewer side-effects., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
28. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.
- Author
-
Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bülow T, Gupta V, Jones NP, Accorinti M, Agarwal M, Batchelor T, Biswas J, Cimino L, tenDam-van Loon NH, de-la-Torre A, Frenkel S, Pe'er J, Kramer M, Miserocchi E, Mochizuki M, Ness T, Rosenbaum JT, Sen HN, Simion M (VRL patient), Sitter H, Vasconcelos-Santos DV, Habot-Wilner Z, Coupland SE, Pulido JS, Smith J, Thorne JE, and Zierhut M
- Subjects
- Biomarkers, Tumor metabolism, DNA Mutational Analysis, Delphi Technique, Humans, Interleukin-10 metabolism, Interleukin-6 metabolism, Intraocular Lymphoma genetics, Intraocular Lymphoma metabolism, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse metabolism, Mutation, Missense, Myeloid Differentiation Factor 88 genetics, Retinal Neoplasms genetics, Retinal Neoplasms metabolism, Retrospective Studies, Surveys and Questionnaires, Vitreous Body metabolism, Intraocular Lymphoma diagnosis, Lymphoma, Large B-Cell, Diffuse diagnosis, Retinal Neoplasms diagnosis, Vitreous Body pathology
- Abstract
Purpose: To provide recommendations for diagnosis of vitreoretinal lymphoma (VRL)., Methods: Literature was reviewed for reports supporting the diagnosis of VRL. A questionnaire (Delphi 1 round) was distributed to 28 participants. In the second round (Delphi 2), items of the questionnaire not reaching consensus (75% agreement) were discussed to finalize the recommendations., Results: Presenting symptoms include floaters and painless loss of vision, vitreous cells organized into sheets or clumps. Retinal lesions are usually multifocal creamy/white in the outer retina. Other findings include retinal lesions with "leopard-skin" appearance and retinal pigment epithelium atrophy. Severe vitreous infiltration without macular edema is the most likely presentation. Diagnostic vitrectomy should be performed. Systemic corticosteroid should be discontinued at least 2 weeks before surgery. An interleukin (IL)-10:IL-6 ratio > 1, positive mutation for the myeloid differentiation primary response 88 gene and monoclonality are indicators of VRL. Multi-modal imaging (optical coherence tomography, fundus autofluorescence) are recommended., Conclusions: A consensus meeting allowed the establishment of recommendations important for the diagnosis of VRL.
- Published
- 2021
- Full Text
- View/download PDF
29. Occlusive retinal vasculopathy with macular branch retinal artery occlusion as a leading sign of atypical hemolytic uremic syndrome - a case report.
- Author
-
González DP, Iglicki M, Svetitsky S, Bar-On Y, Habot-Wilner Z, and Zur D
- Subjects
- Adult, Humans, Male, Retinal Hemorrhage diagnosis, Retinal Hemorrhage etiology, Vitreous Hemorrhage, Atypical Hemolytic Uremic Syndrome diagnosis, Retinal Artery Occlusion diagnosis, Retinal Artery Occlusion etiology, Retinal Diseases
- Abstract
Background: Hemolytic Uremic Syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, considered within the group of thrombocytic microangiopathies. Ocular complications in HUS are very rare. Here, we report an adult patient who suffered from acute onset of paracentral scotoma, caused by branch retinal artery occlusion (BRAO), as a leading symptom of atypical HUS., Case Presentation: A 39-year-old healthy male was lately diagnosed with essential hypertension and mild renal impairment. He complained about acute onset of central scotoma in his left eye. Fundus examination revealed marked narrowing of retinal vessels, cotton wool spots and few retinal hemorrhages in both eyes. The patient was diagnosed with bilateral ischemic retinal vasculopathy and acute macular BRAO in his left eye. Workup revealed thrombocytopenia, worsening renal failure. Renal biopsy showed signs of chronic thrombotic microangiopathy. The patient was diagnosed with atypical HUS (aHUS) and started on plasmapheresis, together with eculizumab. As his condition continued to worsen, he was put on renal replacement therapy. Due to a persistent monoclone of IgG1, the patient underwent bone marrow biopsy which revealed Monoclonal Gammopathy of renal significance, triggering a HUS and treatment was initiated accordingly. Two months after initial presentation, the patient developed neovascularization of the optic disc (NVD) in his left eye, and was treated with 3 monthly intravitreal bevacizumab injections with complete regression of the NVD. The patient suffered from myocardial infarction in the later course and was lost for follow-up. He returned 11 months after the last bevacizumab injection because of sudden loss of vision in his left eye caused by a dense vitreous hemorrhage. Biomicroscopy revealed a new NVD in his right eye. The patient underwent panretinal photocoagulation in both eyes with regression of neovascularization. Vision improved and remained 20/20 in both eyes., Conclusion: We present a case report showing retinal ischemia can be linked with aHUS. As clinal diagnosis might be challenging, physicians should be aware of the rare ocular manifestations of this devastating multi-organ disease. In case of retinal ischemia, panretinal photocoagulation should be initiated soon to avoid blinding complications.
- Published
- 2021
- Full Text
- View/download PDF
30. Endogenous fungal endophthalmitis: risk factors, clinical course, and visual outcome in 13 patients.
- Author
-
Corredores J, Hemo I, Jaouni T, Habot-Wilner Z, Kramer M, Shulman S, Jabaly-Habib H, Al-Talbishi A, Halpert M, Averbukh E, Levy J, Deitch-Harel I, and Amer R
- Abstract
Aim: To analyze the risk factors, ophthalmological features, treatment modalities and their effect on the visual outcome in patients with endogenous fungal endophthalmitis (EFE)., Methods: Data retrieved from the medical files included age at presentation to the uveitis clinic, gender, ocular symptoms and their duration before presentation, history of fever, eye affected, anatomical diagnosis and laboratory evidence of fungal infection. Medical therapy recorded included systemic antifungal therapy and its duration, use of intravitreal antifungal agents and use of oral/intravitreal steroids. Surgical procedures and the data of ophthalmologic examination at presentation and at last follow-up were also collected., Results: Included were 13 patients (20 eyes, mean age 58y). Ten patients presented after gastrointestinal or urological interventions and two presented after organ transplantation. In one patient, there was no history of previous intervention. Diagnostic vitrectomy was performed in 16 eyes (80%) and vitreous cultures were positive in 10 of the vitrectomized eyes (62.5%). In only 4 patients (31%), blood cultures were positive. All patients received systemic antifungal therapy. Sixteen eyes (80%) received intravitreal antifungal agent with voriconazole being the most commonly used. Visual acuity (VA) improved from 0.9±0.9 at initial exam to 0.5±0.8 logMAR at last follow-up ( P =0.03). A trend of greater visual improvement was noted in favor of eyes treated with oral steroids (±intravitreal dexamethasone) than eyes that were not treated with steroids. The most common complication was maculopathy. Twelve eyes (60%) showed no ocular complications., Conclusion: High index of suspicion in patients with inciting risk factors is essential because of the low yield of blood cultures and the good general condition of patients at presentation. Visual prognosis is improved with the prompt institution of systemic and intravitreal pharmacotherapy and the immediate surgical intervention. Oral±local steroids could be considered in cases of prolonged or marked inflammatory responses in order to hasten control of inflammation and limit ocular complications., (International Journal of Ophthalmology Press.)
- Published
- 2021
- Full Text
- View/download PDF
31. Cat Scratch Disease Presenting as Fever of Unknown Origin Is a Unique Clinical Syndrome.
- Author
-
Landes M, Maor Y, Mercer D, Habot-Wilner Z, Bilavsky E, Chazan B, Cohen R, Glikman D, Strahilevitz J, Katzir M, Litachevsky V, Melamed R, Guri A, Shaked H, Perets O, Wiener-Well Y, Stren A, Paul M, Zimhony O, Srugo I, Rahav G, Bishara J, Kuperman AA, Ben-Ami R, Ephros M, and Giladi M
- Subjects
- Adult, Humans, Israel epidemiology, Syndrome, Bartonella henselae, Cat-Scratch Disease complications, Cat-Scratch Disease diagnosis, Cat-Scratch Disease epidemiology, Fever of Unknown Origin diagnosis, Fever of Unknown Origin etiology, Osteomyelitis
- Abstract
Background: Fever of unknown origin (FUO) is a rare manifestation of cat scratch disease (CSD). Data regarding CSD-associated FUO (CSD-FUO), particularly in adults, are limited. We aimed to study disease manifestations and long-term clinical outcome., Methods: A national CSD surveillance study has been conducted in Israel since 1991. Data are obtained using questionnaires, review of medical records, and telephone interviews. FUO was defined as fever of ≥14 days without an identifiable cause. CSD-FUO patients were identified in the 2004-2017 CSD national registry. Follow-up included outpatient clinic visits and telephone/e-mail surveys., Results: The study included 66 CSD-FUO patients. Median age was 35.5 years (range, 3-88). Median fever duration was 4 weeks (range, 2-9). Relapsing fever pattern was reported in 52% of patients, weight loss in 57%, and night sweats in 48%. Involvement of ≥1 organs occurred in 59% of patients; hepatosplenic space-occupying lesions (35%), abdominal/mediastinal lymphadenopathy (20%), ocular disease (18%), and multifocal osteomyelitis (6%) were the most common. Malignancy, particularly lymphoma, was the initial radiological interpretation in 21% of patients; 32% underwent invasive diagnostic procedures. Of the 59 patients available for follow-up (median duration, 31 weeks; range, 4-445), 95% had complete recovery; 3 patients remained with ocular sequelae., Conclusion: This is the first attempt to characterize CSD-FUO as a unique syndrome that may be severe and debilitating and often mimics malignancy. Relapsing fever is a common clinical phenotype. Multiorgan involvement is common. Recovery was complete in all patients except in those with ocular disease., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
32. Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials.
- Author
-
Oron Y, Handzel O, Habot-Wilner Z, Regev K, Karni A, Zur D, Baraquet D, Goldstein M, Elkayam O, and Ungar OJ
- Abstract
Background: Susac syndrome (retino-cochleo-cerebral vasculopathy, SuS) is an autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss. In contrast to data regarding auditory function, data measuring vestibular function is sparse., Objective: To determine whether the video head impulse test (vHIT) can serve as a confirmatory assessment of vestibulocochlear dysfunction in cases of suspected SuS., Methods: Seven patients diagnosed with SuS underwent pure tone audiometry, a word recognition test, cervical vestibular-evoked myogenic potentials (cVEMPs), and the v-HIT., Results: Five patients were diagnosed with definite SuS, and two with probable SuS. Two patients were asymptomatic for hearing loss or tinnitus, and no sensorineural hearing loss was detected by audiograms. Four patients complained of tinnitus, and three patients reported experiencing vertigo. Three patients had abnormal cVEMPs results. All seven patients' vHIT results were normal, except for patient #2, who was one of the three who complained of vertigo. The calculated gain of her left anterior semicircular canal was 0.5, without saccades., Conclusions: This is the first study to describe the results of the vHIT and cVEMPs among a group of patients with SuS. The results suggest that the vHIT should not be the only exam used to assess the function of the vestibular system of SuS patients.
- Published
- 2020
- Full Text
- View/download PDF
33. Recurrent Neuroretinitis: A Unique Presentation of Behçet's Disease in a Child.
- Author
-
Rabina G, Amarilyo G, Zur D, Harel L, and Habot-Wilner Z
- Abstract
We describe a case of Behçet's disease (BD) in a young child that presented with recurrent neuroretinitis and developed retinal lesions during follow-up. A 4.5-year-old girl presented with fever of 39.5°C, erythema nodosum in her legs, bilateral knee arthritis, and perineum aphthae. On ocular examination, visual acuity was 20/25 in both eyes. Right eye examination was normal and the left eye (LE) showed mild anterior and intermediate uveitis, normal optic disc, and a macular star appearance. Laboratory workup demonstrated elevated C-reactive protein levels, a normal abdominal ultrasound, and a normal colonoscopy. The patient was diagnosed with BD. One month post initial presentation, the patient presented with visual acuity of finger counting in the LE with significant anterior uveitis, mild intermediate uveitis, and recurrent neuroretinitis. Under treatment of IV methylprednisolone, oral betamethasone, infliximab, and colchicine, a complete systemic remission was noticed, and uveitis became quiescent. On last examination, 4.5 years post first presentation, visual acuity was 20/25 in both eyes and the LE demonstrated a remnant of a juxtafoveal retinal scar. To the best of our knowledge, this is the first case of neuroretinitis presenting as a manifestation of pediatric BD. Ophthalmologists should be aware of these unique manifestations of ocular BD., Competing Interests: The authors have no financial disclosures., (Copyright © 2020 by S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
34. Standardization of Nomenclature for Ocular Tuberculosis - Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop.
- Author
-
Agrawal R, Agarwal A, Jabs DA, Kee A, Testi I, Mahajan S, McCluskey PJ, Gupta A, Palestine A, Denniston A, Banker A, Invernizzi A, Fonollosa A, Sharma A, Kumar A, Curi A, Okada A, Schlaen A, Heiligenhaus A, Kumar A, Gurbaxani A, Bodaghi B, Islam Shah B, Lowder C, Tappeiner C, Muccioli C, Vasconcelos-Santos DV, Goldstein D, Behra D, Das D, Makhoul D, Baglivo E, Denisova E, Miserocchi E, Carreno E, Asyari F, Pichi F, Sen HN, Uy H, Nascimento H, Tugal-Tutkun I, Arevalo JF, Davis J, Thorne J, Hisae Yamamoto J, Smith J, Garweg JG, Biswas J, Babu K, Aggarwal K, Cimino L, Kuffova L, Agarwal M, Zierhut M, Agarwal M, De Smet M, Tognon MS, Errera MH, Munk M, Westcott M, Soheilian M, Accorinti M, Khairallah M, Nguyen M, Kon OM, Mahendradas P, Yang P, Neri P, Ozdal P, Amer R, Lee R, Distia Nora R, Chhabra R, Belfort R, Mehta S, Shoughy S, Luthra S, Mohamed SO, Chee SP, Basu S, Teoh S, Ganesh S, Barisani-Asenbauer T, Guex-Crosier Y, Ozyazgan Y, Akova Y, Habot-Wilner Z, Kempen J, Nguyen QD, Pavesio C, and Gupta V
- Abstract
Purpose : To standardize a nomenclature system for defining clinical phenotypes, and outcome measures for reporting clinical and research data in patients with ocular tuberculosis (OTB). Methods : Uveitis experts initially administered and further deliberated the survey in an open meeting to determine and propose the preferred nomenclature for terms related to the OTB, terms describing the clinical phenotypes and treatment and reporting outcomes. Results : The group of experts reached a consensus on terming uveitis attributable to tuberculosis (TB) as tubercular uveitis. The working group introduced a SUN-compatible nomenclature that also defines disease "remission" and "cure", both of which are relevant for reporting treatment outcomes. Conclusion : A consensus nomenclature system has been adopted by a large group of international uveitis experts for OTB. The working group recommends the use of standardized nomenclature to prevent ambiguity in communication and to achieve the goal of spreading awareness of this blinding uveitis entity.
- Published
- 2020
- Full Text
- View/download PDF
35. The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma.
- Author
-
Frenkel S, Pe'er J, Kaufman R, Maly B, and Habot-Wilner Z
- Subjects
- Aged, Biomarkers, Tumor metabolism, Female, Humans, Male, Middle Aged, Retrospective Studies, Sensitivity and Specificity, Vitrectomy, Interleukin-10 metabolism, Interleukin-6 metabolism, Lymphoma, B-Cell diagnosis, Lymphoma, T-Cell diagnosis, Retinal Neoplasms diagnosis
- Abstract
Purpose: To evaluate the efficacy of the different diagnostic tests for vitreoretinal lymphoma (VRL)., Methods: A cohort of 150 patients with a presumed diagnosis of VRL. Vitrectomy samples were analysed for cytology, monoclonality [polymerase chain reaction (PCR)] and cytokine levels, and anterior chamber taps were analysed for cytokine levels. Vitreoretinal lymphoma (VRL) was diagnosed after confirming the clinical suspicion with vitreal or brain cytology., Results: Vitreoretinal lymphoma (VRL) was diagnosed in 78 patients. Vitreal cytology was positive for 53/132 patients (40.2%), 36/53 had positive cytology from both the eye and the brain. Additional 25 patients had positive brain cytology. Vitreal PCR for monoclonality was positive for 32/91 patients (35.2%). Vitreal cytokine levels of interleukin (IL)-10/IL-6 were >1 for 47/110 patients (43.1%). For cytology, PCR and cytokine analysis, the respective sensitivity was 73.6%, 46.0% and 81.4%, and the accuracy of the tests was 85.6%, 60.4% and 80.9%, respectively. All three tests were available for 79 patients. In this subset, for cytology, PCR and cytokine analysis the respective sensitivity was 79.5%, 41.0% and 82.1%, respectively, and the accuracy of the tests was 89.9%, 60.8% and 81.0%, respectively., Conclusion: Cytokines analysis has an important role in the diagnosis of VRL. We suggest analysing cytokines levels in all cases suspected of VRL along with cytology and PCR analysis., (© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
36. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant.
- Author
-
Zur D, Iglicki M, Sala-Puigdollers A, Chhablani J, Lupidi M, Fraser-Bell S, Mendes TS, Chaikitmongkol V, Cebeci Z, Dollberg D, Busch C, Invernizzi A, Habot-Wilner Z, and Loewenstein A
- Subjects
- Aged, Aged, 80 and over, Cross-Sectional Studies, Diabetic Retinopathy diagnostic imaging, Diabetic Retinopathy physiopathology, Drug Implants, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Intravitreal Injections, Macular Edema diagnostic imaging, Macular Edema physiopathology, Male, Middle Aged, Retrospective Studies, Tomography, Optical Coherence, Visual Acuity physiology, Biomarkers, Dexamethasone administration & dosage, Diabetic Retinopathy drug therapy, Glucocorticoids administration & dosage, Macular Edema drug therapy, Retinal Neurons pathology
- Abstract
Purpose: To investigate disorganization of retinal inner layers (DRIL) as a biomarker in eyes with diabetic macular oedema (DME) treated by intravitreal dexamethasone (DEX) implant., Methods: Multicentre, retrospective study including eyes with DME treated with DEX implant and follow-up of 12 months after the first injection. OCT scans were evaluated for the presence of DRIL and other structural features. Best corrected visual acuity (BCVA) and central subfield thickness (CST) were recorded at baseline and at 2, 4, 6 and 12 months after treatment. Correlation between DRIL at baseline and outcomes after DEX treatment and the change in DRIL were analysed., Results: A total of 177 eyes (177 patients; naïve, n = 131; refractory, n = 46) were included. Patients without DRIL at baseline gained significantly more vision and enjoyed greater reduction in CST over 12 months (both p = 0.03). DRIL at the boundary between the ganglion cell-inner plexiform complex and inner nuclear layer improved in 48/64 eyes (75%, p < 0.001), while DRIL between the inner nuclear layer and outer plexiform layer improved in 27/77 eyes (35%, p = 0.004)., Conclusions: This is the first study to show that DEX implant has the potential to ameliorate DRIL. Patients without DRIL at baseline have a favourable outcome. DRIL may serve a robust biomarker in DME treated by DEX implant., (© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
37. Demographic and Clinical Features of Pediatric Uveitis in Israel.
- Author
-
Habot-Wilner Z, Tiosano L, Sanchez JM, Shulman S, Barequet D, Rahat O, Amarilyo G, and Amer R
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Incidence, Infant, Infant, Newborn, Israel epidemiology, Male, Retrospective Studies, Risk Factors, Uveitis diagnosis, Tomography, Optical Coherence methods, Uveitis epidemiology, Visual Acuity
- Abstract
Purpose : To report the epidemiology, etiology, ocular characteristics, treatment and visual outcome of pediatric uveitis in Israel. Methods : Retrospective study from two tertiary uveitis centers. Results : Included were 107 patients (182 eyes), 55% females. Mean age at diagnosis 8.8 years. Uveitis was predominantly anterior, idiopathic, bilateral, and chronic. Systemic associations were seen in 36% of patients of which the most common disease was juvenile idiopathic arthritis. Infectious uveitis accounted for 37% of posterior uveitis cases of which toxoplasmosis was the most common cause. Anterior segment complications were commonly observed at presentation (41%); the most predominant were posterior synechiae, cataract, and band keratopathy. The most common posterior segment complications were papillitis, epiretinal membrane, and macular atrophy/scar. Ninety-three percent of eyes had visual acuity >20/40 at last follow-up. Conclusion : The pattern of pediatric uveitis in Israel is similar to that in the western world. Visual outcome was good in most eyes.
- Published
- 2020
- Full Text
- View/download PDF
38. Aminobisphosphonate-associated orbital and ocular inflammatory disease.
- Author
-
Keren S, Leibovitch I, Ben Cnaan R, Neudorfer M, Fogel O, Greenman Y, Shulman S, Zur D, and Habot-Wilner Z
- Subjects
- Adult, Aged, Bone Density Conservation Agents adverse effects, Diphosphonates administration & dosage, Female, Follow-Up Studies, Glucocorticoids therapeutic use, Humans, Inflammation diagnosis, Inflammation drug therapy, Injections, Intravenous, Magnetic Resonance Imaging, Male, Microscopy, Acoustic, Middle Aged, Orbital Diseases diagnosis, Orbital Diseases drug therapy, Prognosis, Retrospective Studies, Tomography, X-Ray Computed, Uveitis diagnosis, Uveitis drug therapy, Young Adult, Diphosphonates adverse effects, Inflammation chemically induced, Orbital Diseases chemically induced, Uveitis chemically induced
- Abstract
Purpose: Aminobisphosphonates may cause orbital/ocular inflammation. Awareness of the clinical presentation and disease course is crucial. The purpose of this study was to analyse demographics, clinical presentation, disease course and treatment of aminobisphosphonate-associated orbital/ocular inflammation in a large series of patients., Methods: A retrospective study of patients with aminobisphosphonate-associated orbital/ocular inflammation and a literature review to differentiate disease presentation and course between various aminobisphosphonates., Results: Eight patients from our institution (6 women and 2 men, median age 62 years) were included. The used drugs were zoledronate, alendronate and risedronate. The most common clinical presentation was conjunctival hyperaemia/chemosis. Scleritis was the most common manifestation, followed by diffuse orbital inflammation and anterior uveitis. Ultrasound aided in diagnosis in all our patients. The aminobisphosphonate was halted in all patients, and some patients had anti-inflammatory treatment. Literature review included 68 patients (83 eyes), of them the most abundant drugs causing orbital/ocular inflammation were pamidronate (38 eyes) and zoledronate (35 eyes). Overall, among 76 patients, all drugs induced orbital disease, while uveitis was induced mostly by zoledronate and pamidronate, less by alendronate and not found among risedronate users. Time interval from drug administration to symptoms was hours to 28 days. Resolution was achieved in all patients, after 1-60 days from disease presentation, and the longer resolution period was found among alendronate users., Conclusion: Orbital/ocular inflammation was mostly caused by intravenous aminobisphosphonates. Uveitis was not induced by risedronate. The putative aminobisphosphonate should be halted at the onset of orbital/ocular involvement and prognosis is favourable., (© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
39. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach.
- Author
-
Habot-Wilner Z, Noronha G, and Wykoff CC
- Subjects
- Choroid, Choroid Diseases diagnosis, Humans, Injections, Intraocular, Retina pathology, Retinal Diseases diagnosis, Tomography, Optical Coherence, Treatment Outcome, Vitreous Body pathology, Anti-Inflammatory Agents administration & dosage, Choroid Diseases drug therapy, Glucocorticoids administration & dosage, Retinal Diseases drug therapy
- Abstract
Delivery of pharmaceuticals to the posterior segment presents challenges that arise from the anatomy and clearance pharmacokinetics of the eye. Systemic and several local administration options [topical, periocular, intravitreal (IVT) and subretinal] are in clinical use, each with a unique benefit to risk profile shaped by factors including the administered agent, frequency of dosing, achievable pharmaceutical concentrations within posterior segment structures versus elsewhere in the eye or the body, invasiveness of the procedure and the inherent challenges with some administration methods. The use of the suprachoroidal space (SCS), which is the region between the sclera and the choroid, is being explored as a potential approach to target pharmacotherapies to the posterior segment via a minimally invasive injection procedure. Preclinical data on agents such as vascular endothelial growth factor inhibitors and triamcinolone acetonide (TA) indicate that administration via suprachoroidal injection results in more posterior distribution of the pharmacologic agent, with higher exposure to the sclera, choroid, retinal pigment epithelium cells and retina, and lesser exposure to the anterior segment, than observed with IVT administration. Based in part on these findings, clinical trials have explored the efficacy and safety of suprachoroidal administration of pharmacologic therapies in conditions affecting the posterior segment. Data on a proprietary formulation of TA administered by suprachoroidal injection show improvement in anatomic and visual outcomes in subjects with noninfectious uveitis, with the potential to mitigate the known risks of cataract and increased intraocular pressure (IOP) associated with the use of intraocular corticosteroids. Suprachoroidal administration appears to be a promising treatment modality and is also in the early stages of investigation for other possible applications, such as injection of antiglaucoma agents into the anterior SCS for long-lasting control of elevated IOP, and as a mode of delivery for gene- or cell-based therapies for retinal disorders., (© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
40. Visual and Clinical Outcome of Macular Edema Complicating Pediatric Noninfectious Uveitis.
- Author
-
Eiger-Moscovich M, Tomkins-Netzer O, Amer R, Habot-Wilner Z, Kasb A, Friling R, and Kramer M
- Subjects
- Biological Factors therapeutic use, Child, Female, Follow-Up Studies, Fundus Oculi, Glucocorticoids therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Macular Edema diagnosis, Macular Edema physiopathology, Male, Prognosis, Retrospective Studies, Uveitis, Intermediate diagnosis, Uveitis, Intermediate drug therapy, Fluorescein Angiography methods, Macula Lutea pathology, Macular Edema etiology, Tomography, Optical Coherence methods, Uveitis, Intermediate complications, Visual Acuity
- Abstract
Purpose: To investigate the clinical course and visual outcome of macular edema (ME) in pediatric patients with chronic noninfectious uveitis., Design: Retrospective case series., Methods: The databases of the uveitis clinics of 4 tertiary medical centers in Israel and the UK were searched for all children treated for uveitic ME in the years 2005-2015. Data were collected from the medical records as follows: demographics, diagnosis, visual acuity, clinical and imaging findings, and treatment given specifically for ME. Findings at baseline and at 3, 6, 12, and 24 months were evaluated., Results: The cohort included 25 children (33 eyes) of mean age 8.5 ± 3.4 years. The most common diagnosis was intermediate uveitis, in 14 children (7 idiopathic, 7 pars planitis). Uveitis was active at ME diagnosis in 28 eyes (84.8%). Median duration of follow-up was 48 months. Median time to resolution of ME was 6 months, with complete resolution in 25 eyes (75.8%) by 24 months. Baseline visual acuity was ≥20/40 in 8 eyes (24.2%), increased to 57.6% at 3 months (P < .0001), and remained stable thereafter. Treatment regimens included corticosteroids (systemically and/or locally), immunosuppression, and biologic therapies. No correlation was found between outcome and either structural characteristics of ME or specific treatment strategy., Conclusions: The prognosis of pediatric uveitic ME is favorable despite its chronic course. Larger randomized controlled trials are needed to define differences among treatment regimens., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. The great imitator on the rise: ocular and optic nerve manifestations in patients with newly diagnosed syphilis.
- Author
-
Klein A, Fischer N, Goldstein M, Shulman S, and Habot-Wilner Z
- Subjects
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Eye Infections, Bacterial complications, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Humans, Male, Middle Aged, Optic Neuritis etiology, Retrospective Studies, Syphilis diagnosis, Young Adult, Eye Infections, Bacterial diagnosis, Optic Nerve pathology, Optic Neuritis diagnosis, Syphilis complications, Syphilis Serodiagnosis methods
- Abstract
Purpose: Ocular manifestations of syphilis have been reported in 2-10% of systemic infection. The purpose of this study was to report the incidence of ocular syphilis and various ocular manifestations, particularly optic nerve involvement, in newly diagnosed cases., Methods: This was a retrospective study. Medical records of newly diagnosed syphilis patients between January 2009 and January 2017 in a tertiary medical centre were reviewed., Results: There were 123 new systemic syphilis cases out of 569,222 (0.02%) admissions to the Tel Aviv Medical Center during the study period. Ninety-three of the 123 patients (76%) underwent ophthalmological examination. Twenty-three of the 93 patients (25%, mean age 48.6 ± 12.9 years, 20 males) had ocular syphilis, and in 12/23 (52%) patients, the ocular symptoms and findings prompted syphilis investigation. Eighteen of the 23 (78%) had optic nerve involvement, and the most common was inflammatory disc oedema. Older age (p = 0.0005) and tertiary stage disease (p = 0.0441) were associated with ocular manifestations and the presence of optic nerve findings. Human immunodeficiency virus (HIV) was associated with ocular but not optic nerve findings. Treatment included intravenous penicillin G, and four patients with severe optic neuropathy were also treated with systemic corticosteroids. Visual acuity significantly improved in most patients (p < 0.05)., Conclusion: Ocular syphilis was found in one-quarter of the patients diagnosed with systemic syphilis and preceded the diagnosis of systemic disease in one-half of them. Optic nerve involvement was a common manifestation. A high index of suspicion for Treponema infection is required in patients presenting with optic nerve involvement to facilitate prompt diagnosis and treatment. Post-treatment visual outcome was good., (© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
42. Herpetic Anterior Uveitis - Analysis of Presumed and PCR Proven Cases.
- Author
-
Neumann R, Barequet D, Rosenblatt A, Amer R, Ben-Arie-Weintrob Y, Hareuveni-Blum T, Vishnevskia-Dai V, Raskin E, Blumenfeld O, Shulman S, Sanchez JM, Flores V, and Habot-Wilner Z
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Aqueous Humor virology, Child, Child, Preschool, Eye Infections, Viral virology, Herpes Zoster Ophthalmicus virology, Humans, Middle Aged, Retrospective Studies, Uveitis, Anterior virology, Young Adult, DNA, Viral analysis, Eye Infections, Viral diagnosis, Herpes Zoster Ophthalmicus diagnosis, Herpesvirus 3, Human genetics, Polymerase Chain Reaction methods, Uveitis, Anterior diagnosis
- Abstract
Purpose: To describe the demographics and clinical characteristics of patients with herpetic anterior uveitis (HAU), and compare characteristics by pathogen, recurrence, and association to iris atrophy., Methods: Multicenter, retrospective study of AU patients diagnosed clinically and by polymerase chain reaction (PCR)., Results: The study included 112 eyes in 109 patients: 54 (48.2%) HSV, 34 (30.4%) VZV, 2 (1.8%) CMV, and 22 (19.6%) unspecified diagnosis. HSV eyes, compared to VZV, had a higher recurrence rate, corneal involvement, KPs, iris atrophy, elevated IOP and posterior synechia (p < 0.05). VZV patients had more frequent immunomodulatory treatments and history of systemic herpetic disease (p < 0.05). Fifty-nine (52.7%) eyes had recurrent disease. Iris atrophy was associated with a higher prevalence of posterior synechia, dilated distorted pupil, and high IOP (p < 0.05)., Conclusion: Different HAU-causing Herpesviridae produce common clinical findings; therefore, PCR should be used more often to confirm specific diagnosis. Iris atrophy was associated with more severe disease.
- Published
- 2019
- Full Text
- View/download PDF
43. Anterior Scleritis Associated with Pemphigus Vulgaris.
- Author
-
Zeeli T, Bar-Ilan E, Habot-Wilner Z, and Sprecher E
- Subjects
- Biopsy, Humans, Male, Mouth Mucosa pathology, Pemphigus diagnosis, Scleritis diagnosis, Young Adult, Pemphigus complications, Sclera pathology, Scleritis etiology
- Abstract
We present a rare co-occurrence of anterior scleritis developing in a patient with recalcitrant pemphigus vulgaris. We discuss the clinical and therapeutic implications of these two conditions and offer concise recommendations.
- Published
- 2019
- Full Text
- View/download PDF
44. Intravitreal Trimethoprim and Sulfamethoxazole Toxicity to the Retina of Albino Rabbits.
- Author
-
Mazza O, Habot-Wilner Z, Shahar J, Mann I, Loewenstein A, and Perlman I
- Abstract
Purpose: To evaluate retinal toxicity of intravitreal trimethoprim-sulfamethoxazole (TMP-SMX) in an albino rabbit model., Methods: Albino rabbits ( N = 10) were treated in the right eye with the maximum intravitreal dose of TMP-SMX mixture (1600 μg/8000 μg /0.1 mL), while 0.1 mL saline was injected into the vitreous of the left eye. Clinical examination and electrophysiological (electroretinogram [ERG] and visual evoked potentials [VEPs]) testing were conducted before injection, 3 days, 1, 2, and 4 weeks postinjection. Retinal structure and expression of glial fibrillary acidic protein (GFAP) were assessed from histology and immunocytochemistry respectively at the end of the follow-up period., Results: Clinical examination was normal throughout the follow-up period. ERG responses from the experimental eyes were similar to those recorded from the control eyes, but the sum of oscillatory potentials decreased in the experimental eyes at 2 weeks postinjection. The VEP responses, elicited by stimulation of the experimental eyes, were abnormal having reduced amplitude and prolonged implicit time. Histological damage in the experimental eyes was expressed by thickness reduction of whole, outer, and inner nuclear layers. GFAP was expressed in retinal Müller cells of all experimental eyes, but none of control eyes., Conclusions: A single intravitreal injection of TMP-SMX mixture (1600 μg/8000 μg, respectively) causes functional and structural damage to the inner retina and retinal output. Signs of retinal stress were also evident by GFAP expression in retinal Müller cells of all experimental eyes. Therefore, the use of TMP-SMX via intravitreal administration should be done with caution., Translational Relevance: These findings highlight the risk of retinal toxicity after intravitreal injection of trimethoprim-sulfamethoxazole and emphasize that this treatment should be carefully considered.
- Published
- 2018
- Full Text
- View/download PDF
45. Cat-scratch disease: ocular manifestations and treatment outcome.
- Author
-
Habot-Wilner Z, Trivizki O, Goldstein M, Kesler A, Shulman S, Horowitz J, Amer R, David R, Ben-Arie-Weintrob Y, Bakshi E, Almog Y, Sartani G, Vishnevskia-Dai V, Kramer M, Bar A, Kehat R, Ephros M, and Giladi M
- Subjects
- Adolescent, Adult, Aged, Antibodies, Bacterial analysis, Bartonella henselae genetics, Bartonella henselae immunology, Cat-Scratch Disease complications, Cat-Scratch Disease drug therapy, Child, DNA, Bacterial analysis, Eye Infections, Bacterial drug therapy, Eye Infections, Bacterial microbiology, Female, Fluorescein Angiography methods, Fundus Oculi, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Vision Disorders diagnosis, Vision Disorders physiopathology, Young Adult, Anti-Bacterial Agents therapeutic use, Bartonella henselae isolation & purification, Cat-Scratch Disease diagnosis, Eye Infections, Bacterial diagnosis, Glucocorticoids therapeutic use, Vision Disorders etiology, Visual Acuity
- Abstract
Purpose: To characterize cat-scratch disease (CSD) ocular manifestations and visual outcome and evaluate the effect of systemic antibiotics and corticosteroids on final visual acuity (VA)., Methods: Multicentre retrospective cohort study. Medical records of 86 patients with ocular disease (107 eyes) of 3222 patients identified in a national CSD surveillance study were reviewed., Results: Mean age was 35.1 ± 14.2 years. Median follow-up was 20 weeks (range 1-806 weeks). Of 94/107 (88%) eyes with swollen disc, 60 (64%) had neuroretinitis at presentation, 14 (15%) developed neuroretinitis during follow-up, and 20 (21%) were diagnosed with inflammatory disc oedema. Optic nerve head lesion, uveitis, optic neuropathy and retinal vessel occlusion were found in 43 (40%), 38 (36%), 34 (33%) and 8 (7%) eyes, respectively. Good VA (better than 20/40), moderate vision loss (20/40-20/200) and severe vision loss (worse than 20/200) were found in 26/79 (33%), 35/79 (44%) and 18/79 (23%) eyes at baseline and in 63/79 (80%), 11/79 (14%) and 5/79 (6%) eyes at final follow-up, respectively (p < 0.001). Significant VA improvement (defined as improvement of ≥3 Snellen lines at final follow-up compared to baseline) occurred in 12/24 (50%) eyes treated with antibiotics compared with 14/16 (88%) eyes treated with antibiotics and corticosteroids (p = 0.02). Multivariate logistic regression was suggestive of the same association (odds ratio 7.0; 95% CI 1.3-37.7; p = 0.024)., Conclusion: Optic nerve head lesion is a common and unique manifestation of ocular CSD. Most patients improved and had final good VA. Combined antibiotics and corticosteroid treatment was associated with a better visual outcome., (© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
46. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
- Author
-
Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R, Neumann R, and Kramer M
- Subjects
- Adolescent, Antirheumatic Agents therapeutic use, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Treatment Outcome, Uveitis etiology, Adalimumab therapeutic use, Arthritis, Juvenile complications, Behcet Syndrome complications, Infliximab therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors, Uveitis drug therapy
- Abstract
Purpose: This study aimed to report the clinical outcome of children with uveitis treated with anti-tumor necrosis factor alpha (TNF-α) agents., Methods: This included a retrospective cohort study. Children with uveitis treated with infliximab or adalimumab in 2008-2014 at five dedicated uveitis clinics were identified by database search. Their medical records were reviewed for demographic data, clinical presentation, ocular complications, and visual outcome. Systemic side effects and the steroid-sparing effect of treatment were documented., Results: The cohort included 24 patients (43 eyes) of whom 14 received infliximab and 10 received adalimumab after failing conventional immunosuppression therapy. Mean age was 9.3 ± 4.0 years. The most common diagnosis was juvenile idiopathic arthritis-related uveitis (n = 10), followed by Behçet's disease (n = 4), sarcoidosis (n = 1), and ankylosing spondylitis (n = 1); eight had idiopathic uveitis. Ocular manifestations included panuveitis in 20 eyes (46.5%), chronic anterior uveitis in 19 (44.2%), and intermediate uveitis in 4 (9.3%). The duration of biologic treatment ranged from 6 to 72 months. During the 12 months prior to biologic treatment, while on conventional immunosuppressive therapy, mean visual acuity deteriorated from 0.22 to 0.45 logMAR, with a trend of recovery to 0.25 at 3 months after initiation of biologic treatment, remaining stable thereafter. A full corticosteroid-sparing effect was demonstrated in 16 of the 19 patients (84.2%) for whom data were available. Treatment was well tolerated., Conclusions: Treatment of pediatric uveitis with anti-TNF-α agents may improve outcome while providing steroid-sparing effect, when conventional immunosuppression fails. The role of anti-TNF-α agents as first-line treatment should be further investigated in controlled prospective clinical trials.
- Published
- 2018
- Full Text
- View/download PDF
47. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
- Author
-
Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, and Goldstein M
- Subjects
- Administration, Oral, Adolescent, Adult, Aged, Central Serous Chorioretinopathy diagnosis, Central Serous Chorioretinopathy physiopathology, Choroid drug effects, Chronic Disease, Dose-Response Relationship, Drug, Double-Blind Method, Eplerenone, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mineralocorticoid Receptor Antagonists administration & dosage, Prospective Studies, Spironolactone administration & dosage, Time Factors, Treatment Outcome, Young Adult, Central Serous Chorioretinopathy drug therapy, Choroid pathology, Fluorescein Angiography methods, Spironolactone analogs & derivatives, Tomography, Optical Coherence methods, Visual Acuity
- Abstract
Purpose: To evaluate the efficacy and safety of eplerenone for chronic nonresolving central serous chorioretinopathy (CSC)., Methods: Prospective, double-blind, randomized placebo-controlled study. Nineteen eyes of 17 patients with persistent subretinal fluid (SRF) due to CSC were enrolled and randomized to receive eplerenone 50 mg/day or placebo for 3 months, followed by a 3-month follow-up. The main outcome measure was change in SRF from baseline to 3 months of treatment. Secondary outcomes included change in SRF at any time-point, complete resolution of SRF, improvement in choroidal thickness and change in best-corrected visual acuity (BCVA)., Results: Thirteen eyes were treated with eplerenone and six with placebo. Both groups showed reduction in SRF throughout the treatment period, with a significant reduction at months 1, 3 and 5 only in the treatment group. Twenty-three per cent in the treatment group and 30.8% per cent in the placebo group experienced complete resolution of SRF. A significant improvement in BCVA was noted in the placebo group at 4 months, as well as a significant difference in BCVA between groups at 3 months in favour of the placebo group (p = 0.005). There was no significant difference in choroidal thickness in either group throughout the study period. No adverse events related to eplerenone were noted in the treatment group., Conclusion: In this study, eplerenone was not found to be superior to placebo in eyes with chronic CSC., (© 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
48. Safety of intravitreal clindamycin in albino rabbit eyes.
- Author
-
Habot-Wilner Z, Mazza O, Shahar J, Massarweh A, Mann I, Loewenstein A, and Perlman I
- Subjects
- Animals, Electroretinography drug effects, Evoked Potentials, Visual drug effects, Evoked Potentials, Visual physiology, Intravitreal Injections, Rabbits, Retina physiopathology, Anti-Bacterial Agents toxicity, Clindamycin toxicity, Retina drug effects
- Abstract
Purpose: To study the potential toxic effects of intravitreal clindamycin on the retina of albino rabbits, by assessing functional and morphological retinal changes., Methods: Eight albino rabbits were included in the study. In each rabbit, 1 mg/0.1 ml clindamycin was injected into the vitreous of the right (experimental) eye, and 0.1 ml saline was injected into the vitreous of the left (control) eye. The electroretinogram (ERG) was recorded before injection, 3 days, 1, 2, and 4 weeks post-injection. The visual evoked potential (VEP) was recorded 4 weeks post-injection. Clinical examination was conducted at all time points. The eyes were enucleated at the termination of the follow-up period in order to prepare the retinas for histology in order to assess retinal structure., Results: ERG and VEP responses that were recorded from the experimental eye at different times following intravitreal clindamycin injection were very similar to the corresponding responses that were recorded from the control eyes. Clinical examination was normal in all eyes, and no histological damage was observed., Conclusions: Intravitreal injection of 1 mg clindamycin does not cause functional or morphological signs of retinal toxicity in albino rabbits, during a period of 4 weeks post-injection. These findings support the clinical use of 1 mg intravitreal clindamycin.
- Published
- 2017
- Full Text
- View/download PDF
49. Association Between Non-Infectious Uveitis and Thyroid Dysfunction: A Case Control Study.
- Author
-
Rosenblatt A, Zaitoon H, and Habot-Wilner Z
- Subjects
- Adult, Aged, Case-Control Studies, Female, Humans, Hyperthyroidism complications, Hyperthyroidism epidemiology, Hypothyroidism complications, Hypothyroidism epidemiology, Male, Middle Aged, Retrospective Studies, Thyroid Diseases complications, Thyroid Diseases epidemiology, Uveitis complications, Uveitis epidemiology
- Abstract
Background: Several reports suggested a relation between uveitis and thyroid disease or dysfunction. However, no study has investigated the association between uveitis and thyroid dysfunction. The purpose of this study was to compare the prevalence of thyroid dysfunction in patients with and without non-infectious uveitis., Methods: This was a retrospective, case-control study., Results: Two hundred thirty-five non-infectious uveitis patients (uveitis group) and 600 controls (control group) were included in the study, of whom 492 (58.9%) were females. No differences were demonstrated between the uveitis and control groups with regard to baseline characteristics, including age, sex, and the presence of systemic diseases such as diabetes, hypertension, and cardiac disease. Rheumatologic and gastrointestinal disease were more common in the uveitis group (p < 0.001 and p = 0.007, respectively). Overall, thyroid dysfunction was noted in 61 (7.3%) patients, of whom 55 had hypothyroidism and six had hyperthyroidism. Seventeen out of 235 (7.2%) uveitis patients and 44/600 (7.3%) controls were diagnosed with thyroid dysfunction-a similar proportion in both groups (p = 0.96). Of these, all uveitis patients and 38 (86.4%) patients in the control group had a diagnosis of hypothyroidism (p = 0.63). A higher percentage of women was found among uveitis patients with thyroid dysfunction compared with uveitis patients without thyroid dysfunction (p = 0.002). The most common uveitis type was anterior uveitis. No significant difference was found in uveitis types between patients with or without a diagnosis of thyroid dysfunction., Conclusions: The prevalence of thyroid dysfunction was similar in both groups, and no association was found between non-infectious uveitis and thyroid dysfunction in this study. These findings suggest there is no need for routine thyroid function evaluation in patients with non-infectious uveitis.
- Published
- 2017
- Full Text
- View/download PDF
50. High-resolution ultrasound biomicroscopy as an adjunctive diagnostic tool for anterior scleral inflammatory disease.
- Author
-
Zur D, Neudorfer M, Shulman S, Rosenblatt A, and Habot-Wilner Z
- Subjects
- Adolescent, Adult, Aged, Child, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Scleritis classification, Visual Acuity, Young Adult, Anterior Eye Segment diagnostic imaging, Microscopy, Acoustic, Scleritis diagnostic imaging
- Abstract
Purpose: To study high-resolution ultrasound biomicroscopy (UBM) findings in anterior scleral inflammatory disease and evaluate the efficacy of high-resolution UBM as an adjunctive diagnostic tool., Methods: A cross-sectional study. The medical records of 30 patients (33 eyes) with episcleritis or anterior scleritis were reviewed for clinical features and high-resolution UBM findings. Ultrasound biomicroscopy (UBM) examination was performed using 50 MHz Aviso S (Quantel Medical, Clermont-Ferrand, France)., Results: Seventeen eyes had episcleritis [nodular (12), simple (five)], and 16 eyes had anterior scleritis [nodular (14), diffuse (two)] as classified by UBM. The use of high-resolution UBM allowed high-resolution imaging of the sclera and episclera and showed characteristic patterns of episcleritis and anterior scleritis. The clinical classification matched UBM findings in 25 (76%) eyes. In the other eight eyes (24%), UBM analysis led to a change in the final classification: four eyes with suspected episcleritis were classified with scleritis, and four eyes with suspected scleritis were classified with episcleritis. Eleven patients (36.7%) had an associated systemic disease., Conclusion: High-resolution UBM enabled visualization of distinct imaging findings of episcleritis and anterior scleritis, indicating its usefulness in the classification of challenging cases of anterior scleral inflammatory disease., (© 2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.